terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 29, 2026

ING posts FY2025 net result of €6,327 million, driven by continued growth in customer balances and fee income

View original at finance.yahoo.com
ING posts FY2025 net result of €6,327 million, driven by continued growth in customer balances and fee income ING Group ING posts FY2025 net result of €6,327 million, driven by continued growth in customer balances and fee income Full-year profit before tax of €9,148 million and full-year return on equity of 13.2% • Mo…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We have delivered strong commercial growth while achieving €23.0 billion in total income

    80% confidence
  • In 2025, amid ongoing geopolitical uncertainty, we have consistently executed our strategy of accelerating growth, increasing impact and further diversifying our income by doing more business with more customers and clients

    80% confidence
  • Our mobile primary customer base has increased by over one million, fully in line with our target, bringing us to more than 15 million mobile primary customers out of nearly 41 million total customers

    80% confidence
  • We remain confident that our strategy positions us to create value for all our stakeholders by supporting more customers and clients, and by diversifying income streams

    80% confidence
  • We achieved strong volume growth, including €56.9 billion in lending growth, more than double the amount of the previous year

    80% confidence
  • We remain committed to supporting our clients in their sustainability transitions

    80% confidence
  • ING's management of ESG material risk is 'Strong' with an ESG risk rating of 18.0 (low risk)

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com